Melanie Nallicheri - Foundation Medicine Chief business Officer and head of Biopharma
Executive
Ms. Melanie Nallicheri is cheif business officer and head of biopharma of company.she joined Foundation Medicine in October 2016 as Chief Business Officer and Head of BioPharma. Prior to joining Foundation Medicine, from September 2013 to June 2016, Ms. Nallicheri was Senior Vice President, Corporationrationrate Strategy and Business Development at McKesson Distribution Solutions and McKesson Data Analytics. From April 2011 to September 2013, Ms. Nallicheri was Senior Vice President, Corporationrationrate Development at Geron Corporationrationration. From January 1993 to February 2011, she was a partner and senior member of the global health practice at Booz CompanyBooz Allen Hamilton. She has served on the board of directors at the American Red Cross Bay Area Chapter, Bay Area Council and Healthcare Business Womens Association since 2016.
| Age | 48 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 617 418-2200 |
| Web | www.foundationmedicine.com |
Foundation Medicine Management Efficiency
Foundation Medicine's management efficiency ratios could be used to measure how well Foundation Medicine manages its routine affairs as well as how well it operates its assets and liabilities.The company has 90 M in debt with debt to equity (D/E) ratio of 476.2, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Foundation Medicine has a current ratio of 2.22, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Foundation Medicine until it has trouble settling it off, either with new capital or with free cash flow. So, Foundation Medicine's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Foundation Medicine sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Foundation to invest in growth at high rates of return. When we think about Foundation Medicine's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robin Lybeck | Celsius Holdings | N/A | |
| Evan Pondel | Crimson Wine | N/A | |
| Brian Franz | Diageo PLC ADR | 53 | |
| Brant Burchfield | Celsius Holdings | N/A | |
| Alecia Bailey | Assurant | N/A | |
| Nicolas Quille | Crimson Wine | 50 | |
| Sean Moshier | Assurant | N/A | |
| Michael Joyce | Sun Life Financial | N/A | |
| Paul Wiseman | Celsius Holdings | N/A | |
| Manuel Becerra | Assurant | 60 | |
| Thomas Shropshire | Diageo PLC ADR | N/A | |
| Sally Grimes | Diageo PLC ADR | 53 | |
| Claude Sarfo | Assurant | N/A | |
| Syl Saller | Diageo PLC ADR | 60 | |
| Karen Diepholz | Crimson Wine | 59 | |
| Gregory DeChurch | Assurant | N/A | |
| Edward Pilkington | Diageo PLC ADR | N/A | |
| Kyle Watson | Celsius Holdings | N/A | |
| Sylvia Saller | Diageo PLC ADR | 60 | |
| Edwin NegronCarballo | Celsius Holdings | 62 | |
| Yvonne Harrison | Diageo PLC ADR | N/A | |
Management Performance
| Return On Equity | -2.0E-4 | |||
| Return On Asset | -1.0E-4 |
Foundation Medicine Leadership Team
Elected by the shareholders, the Foundation Medicine's board of directors comprises two types of representatives: Foundation Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Foundation. The board's role is to monitor Foundation Medicine's management team and ensure that shareholders' interests are well served. Foundation Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Foundation Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Day, Director | ||
| Michael Varney, Director | ||
| Krishna Yeshwant, Independent Director | ||
| David Daly, Chief Commercial Officer | ||
| David Schenkein, Independent Director | ||
| Melanie Nallicheri, Chief business Officer and head of Biopharma | ||
| Alexis Borisy, Chairman of the Board, Co-Founder | ||
| Steven Kafka, Pres and COO | ||
| Evan Jones, Independent Director | ||
| Vincent Miller, Chief Medical Officer | ||
| Konstantin Fiedler, COO | ||
| Michael Pellini, President CEO, Director | ||
| Robert Hesslein, Senior Vice President General Counsel | ||
| Sandra Horning, Director | ||
| Michael Doherty, Head of Product Development | ||
| Jason Ryan, CFO | ||
| Michael Dougherty, Director | ||
| Tom Civik, Chief Commercial Officer | ||
| Troy Cox, CEO, Director | ||
| Thomas Civik, Chief Commercial Officer |
Foundation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Foundation Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.0E-4 | |||
| Return On Asset | -1.0E-4 | |||
| Profit Margin | (0.0001) % | |||
| Operating Margin | (83.98) % | |||
| Current Valuation | 5.09 B | |||
| Shares Outstanding | 37.14 M | |||
| Shares Owned By Insiders | 58.74 % | |||
| Shares Owned By Institutions | 36.24 % | |||
| Number Of Shares Shorted | 2.35 M | |||
| Price To Earning | (9.70) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Foundation Stock
If you are still planning to invest in Foundation Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Foundation Medicine's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world |